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ity-adjusted life-years (QALYs), was calculated for patients receiving ADAMTX,
IFXMTX, and MTX alone. Outcomes were examined separately for MTX-naïve and
disease-modifying antirheumatic drug (DMARD)–failure patients. Treatment ben-
efits were measured by American College of Rheumatology 20, 50, and 70 responses
and translated into improvements in Health Assessment Questionnaire Disability
Index scores. Risks comprised loss of drug efficacy and adverse events; patients
could withdraw from treatment due to either. Benefits and risks were associated
with increments and decrements in QALYs, respectively. Data were derived from
the published literature and drug prescribing information. RESULTS: MTX-naïve
patients on ADAMTX, IFXMTX, and MTX alone withdrew after 3.31, 2.46, and
2.71 years and accrued NHBs of 1.40, 1.05, and 1.08 QALYs, respectively. Thus,
MTX-naïve patients on ADAMTX accrued incremental NHBs of 0.35 (P  .05) ver-
sus IFXMTX and 0.32 (P  .05) versus MTX alone. DMARD-failure patients on
ADAMTX, IFXMTX, and MTX alone withdrew after 3.33, 2.11, and 1.44 years and
accrued NHBs of 1.38, 0.86, and 0.57 QALYs, respectively. Thus, DMARD-failure
patients on ADAMTX incurred incremental NHBs of 0.51 (P .05) versus IFXMTX
and 0.81 (P  .05) versus MTX alone. CONCLUSIONS: Understanding the benefit-
risk tradeoff is important for clinicians when prescribing anti-TNFs. Both MTX-
naïve and DMARD-failure patients may experience greater NHB when treated with
ADAMTX than when treated with IFXMTX or MTX alone.
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The GO-REVEAL clinical trial has shown golimumab to be effective in the treatment
of active and progressive PsA. A recently published article by Yang et al. that cov-
ered the NICE technology appraisal process for psoriatic arthritis (TA220) presented
an indirect comparison that suggested differences in treatment effects between
different anti-Tumor Necrosis Factor-ainhibitors (TNFs). OBJECTIVES: To evaluate
the comparative efficacy of anti-TNF drugs for the treatment of PsA in patients with
an inadequate response to disease-modifying anti-rheumatic drugs (DMARDs) us-
ing a a critical appraisal of the Yang et al. manuscript and network meta-analysis.
METHODS: The previous indirect comparison was analysed, identified errors cor-
rected, and assumptions altered where necessary. A network meta-analysis was
then performed based on these updated parameters. Indirect comparisons were
performed for the available anti-TNFs (adalimumab, etanercept, golimumab, and
infliximab) measuring relative risks for the PsA response criteria (PsARC), mean
differences for improvements from baseline for the Health Assessment Question-
naire (HAQ) by PsARC responders and non-responders, and mean difference for the
improvements from baseline for the psoriasis area and severity index (PASI). When
the reporting of data on intervention group response rates and improvements were
incomplete, straightforward conversions were used, based on the available data.
RESULTS: All anti-TNFs were significantly better than control. The indirect com-
parison did not reveal any statistically significant difference between the anti-TNFs
using the updated parameters. CONCLUSIONS: There is insufficient statistical ev-
idence to demonstrate differences in efficacy between available anti-TNFs for PsA.
Estimates of effect appear to be sensitive to the analytic approach, so this uncer-
tainly should be taken into account in future economic evaluations.
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OBJECTIVES: Chronic inflammation in rheumatoid arthritis (RA) may interfere
with bone remodelling. Small studies have suggested biologic DMARDs preserve
bone mineral density at 6-12 months. Our objective was to determine the risk of
non-vertebral osteoporotic fractures in RA subjects aged50, comparing outcomes
in patients who were exposed or unexposed to biologic DMARDs. METHODS: A
nested case-control study from January 2002 to December 2008 was conducted
using Quebec physician billing and hospital discharge data. RA subjects were iden-
tified from ICD-9/10 codes in billing and hospitalization data. Subjects were fol-
lowed until the earliest of non-vertebral osteoporotic fracture (index date), death,
or end of study period. A validated algorithm identified non-vertebral osteoporotic
fractures from physician claims. Controls were matched to cases (4:1 ratio) on age,
sex, and date of study entry. Biologic DMARD exposure was defined as being on
treatment for 180 days pre-index. Conditional logistic regression was used, ad-
justing for indicators of RA severity, comorbidity, drugs influencing fracture risk,
and measures of health care utilization. RESULTS: Over the study period, 1,803
cases were identified (7,175 controls). The most frequent fracture site was hip/
femur (43.7%). In total, 190 subjects (53 cases, 137 controls) were exposed to biologic
DMARDs. We were unable to demonstrate an association between biologic
DMARDs and fracture risk (Odds Ratio, OR [95% Confidence Interval, CI]: 1.16 [0.51-
2.62]). RA duration had the strongest impact on fracture risk; for subjects of RA
duration10 years (vs.5), the OR was 6.40 (95% CI 3.57-11.46), while those with RA
duration 5-10 years (vs. 5) had an OR of 3.05 (95%CI 1.90-4.89). The inability to
detect an effect remained in sensitivity analyses. CONCLUSIONS: Despite the pos-
itive impact of biologic DMARDs on bone remodelling observed in small studies, we
were unable to demonstrate a reduction in the risk of non-vertebral osteoporotic
fractures in older adults with RA.
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OBJECTIVES: In Italy the epidemiological data and the Dupuytren disease care
practice description are poor and come mainly from extrapolation of data obtained
in other countries. The objective of this study was to assess the prevalence and the
management of this disease in Italy and in the Italian regions. METHODS: Data
have been obtained from CSD LPD General Practitioner’s (GPs) longitudinal data-
base. Patients with at least one diagnosis of Dupuytren disease between October
2008 and September 2010 were selected. Patients were followed-up for 12 months
since the First Diagnosis date. Study results have been stratified by macro areas.
RESULTS: 1.829 patients (62,55% men, 37,45% women) with at least one diagnosis of
Dupuytren disease have been selected. Disease prevalence was estimated at 0,15%
patients nationwide and at 0.178% , 0.229%, 0.123% ,0.082% patients in the Nord-
West, Nord-East, Center and South-Islands respectively. Prevalence increased with
age: 35% of the patients were aged over 65 y. Only 32 % of the patients benefited
from a specialist visit request for the Dupuytren disease during the follow-up pe-
riod; 70,7% of those requests were for orthopedic visits, 13,5% for hand surgery and
7,5% for physiatry. Macro area analysis showed some differences in the specialists
visits distribution. CONCLUSIONS: The prevalence analysis showed a slight differ-
ence among macro areas underlining a major prevalence of the disease in the
Nord-East compared to the South–Islands area. The prevalence of the disease in the
CSD LPD database in Italy was of 0.15% which is significantly lower than that
reported in the literature. This is probably due to the fact that the majority of
Dupuytren published studies were conducted in Nordic countries where the dis-
ease is mainly diffused. Also, the data collection methods and the age groups could
be different, and, further, many researches were carried out in a specialist setting
only.
MUSCULAR-SKELETAL DISORDERS - Cost Studies
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OBJECTIVES: To model the annual impact on hospital costs following the introduc-
tion of sugammadex for routine reversal of neuromuscular blockade. METHODS:
An economic model reflecting resource use and costs associated with neuromus-
cular block and its reversal, and residual blockade, was constructed for a typical
Greek hospital. Clinical trial data were used to estimate time savings relating to
shortened reversal in the operating room (OR) for sugammadex compared to
neostigmine and no reversal. Costs of OR time were derived from labor costs for
different types of OR staff. Resource use associated with residual blockade sequelae
(aspiration, hypoxemia, muscle weakness, upper airway obstruction) was esti-
mated from the literature. Annual procedures, utilization of neuromuscular block-
ing and reversal agents, and uptake of sugammadex within a typical Greek hospital
were estimated. Unit costs were based on public data sources or published
literature. RESULTS: If all OR staff modeled (with average staff attendance across
all procedures of 2.4 anesthetists, 3.5 surgeons and 3.7 nurses) can realize time
savings with shortened reversal, use of sugammadex is estimated to save a typical
Greek hospital, using sugammadex in 7,130 procedures annually, 23,717 € per year.
This corresponds to an increase in drug costs of 358,963 €, which is more than fully
offset by a decrease in costs of OR staff and clinical sequelae of residual blockade
(-382,680 €). In a worst case scenario, if only one second degree anesthetist, one
second degree surgeon and one nurse in attendance realize time savings, annual
costs would be increased (198,404 €). Results were sensitive to OR staff costs and
time savings. CONCLUSIONS: Sugammadex for routine reversal of neuromuscular
blockade can potentially lead to cost savings in the Greek health care setting. The
degree to which costs may be saved depends upon which OR staff can realize time
savings with shortened reversal.
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OBJECTIVES: To assess differences in treatment costs for patients with anti-TNFs
for ankylosing spondylitis (AS) and rheumatoid arthritis (RA), according to their
route of administration. METHODS: A budget impact analysis was designed to
study the costs of each administration route, whether administered subcutane-
ously (SC) in the ambulatory setting or administered intravenously (IV) in an out-
patient hospital setting, from the perspective of the French Statutory Health Insur-
ance. Costs and tariffs are official statutory tariffs. The dosages of each treatment
stem from the Summary of Product Characteristics. Costs were followed-up over 2
years (induction  maintenance). For the weight, a gold standard of 70 kg was
considered. Scenarios were modeled for cohorts of 100 patients. Costs for nurse
have been systematically taken into account for each SC injection associated to a
specialist consultation every 3 months. Initially for IV drugs no ambulatory addi-
tional costs and no transportation costs were considered. RESULTS: For AS, the
average cost for SC drugs over 2 years was 23 471€ while it was 31 086€ for infusion
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drugs. For RA, average cost for SC drugs was 24 448€ and it was 30 403€ for the
infusion drugs. For 100 AS patients treated over 2 years, substituting 60% of IV by SC
drugs would generate 353 013€ in savings for the French Statutory health insur-
ance. For RA, such a substitution would yield a 487 977€ saving. Taking into account
transportation costs of 50€ per visit increased respectively the costs associated
with infusion therapies to 31 153€ for AS and 31 085€ for RA. CONCLUSIONS: In the
context of ever-increasing scrutiny over public health care expenditure, differ-
ences in costs should drive the choice of treatment route of administration. Over-
all, replacing current IV Anti-TNF therapies by SC treatments would entail substan-
tial benefits for the French Statutory Health Insurance.
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OBJECTIVES: To estimate the budget impact analysis of Collagenase Clostridium
histolyticum (CCH) vs. fasciectomy (FSC) for the treatment of Dupuytren’s Disease
(DD) in Spain.METHODS: A cost minimization analysis was adopted (effectiveness
was assumed to be equivalent for both techniques). DD related costs were consid-
ered: CCH costs (including drug, administration and visits) were obtained from
clinical trials and a real-life study. FSC costs (including type of admission, visits,
emergency room, re-admissions, tests, drugs and rehabilitation costs) were col-
lected through a retrospective, observational, local study. Unit costs were obtained
from local databases (e-SALUD and BOT). Results were presented from the NHS
perspective for the next 3 years. We assumed 5100 fasciectomies/year (5% annu-
ally) and a 20, 30 and 40% of them will annually utilize CCH. In addition a 10, 15 and
20% of untreated diagnosed patients were expected to receive CCH. All the data
were validated through an expert panel. A sensitivity analysis was performed with
the main variables. RESULTS: The average FSC cost was € 2250 (72% inpatients),
ranging from € 1703 to € 2467 for outpatients and inpatients respectively. The
average CCH cost was € 1220 (1.5 vial/injection and 4 visits) and may drop to € 898
(1.1 vial/injections and 3 visits). The accumulated 3 years BIA was 45,971 € [M€
-2.993, 3.870]. CONCLUSIONS: According to this study, the inclusion of the CCH
produced a 3 years cumulative budgetary impact of € 45,971 [M€ -2.993, 3.870] for
the NHS.
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OBJECTIVES: To estimate the budget impact of adopting golimumab for the treat-
ment of rheumatoid arthritis (RA), akylkosing spondilitis (AS) and psoriatic arthris-
tis (PsA) in the Brazilian public health care system (SUS). METHODS: In Brazil, four
anti-TNF biologics are approved for treatmenting RA, AS and PsA: adalimumab,
etanercept, infliximab, and golimumab. However, only the former three are reim-
bursed in the SUS. Using the public database, DATASUS, the number of patients
receiving anti-TNF treatment for RA, AS and PsA (based on ICD9 codes) was gath-
ered for the last 12 months, along with the associated drug costs. As golimumab is
not yet reimbursed, treatment cost was defined according to law, based on the
mandatory government discount of 21,87% . RESULTS: Around 38.687 patients
received treatment with adalimumab (18.802), etanercept (14.614) and infliximab
(6.840) between March 2011 and February 2012 in the SUS for RA, AS and PsA. In
total, public health care spending with these treatments was about R$
1.005.311.920,00 for the three indications in the same period (average treatment
cost/patient R$ 25.985,78). Assuming the adoption of golimumab in 30% of patients
receiving subcutaneous treatment (adalimumab and etanercept), the budget will
be reduced by about R$ 101 million (11%) in the first year, excluding taxes. These
savings represent over 6.238 new patients/year that can receive treatment with
golimumab for RA, AS, and PsA. The savings can reach up to R$ 303 million /year, if
golimumab is adopted as first choice among subcutaneous anti-TNF treatments.
CONCLUSIONS: With the lowest treatment cost, golimumab has the potential to
reduce public expenditure across all three indications in the SUS. These savings
have important benefits for payers and patients, such as an increase in access to
treatment or investment in other health priorities. Furthermore, with the least
frequent dosing, golimumab presents important advantages in terms of patient
commodity and logistics.
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OBJECTIVES: To estimate the budget impact for the treatment of osteoporosis in
Italy following a treatment pattern with TERIPARATIDE vs. PTH 1-84. METHODS: A
budget impact model was constructed using a decision-tree analysis with a Monte
Carlo technique where a sufficiently large number (currently 500) of individual
patients are processed through the model, saving the result for each patient and
calculating a mean group cost. The model incorporates the vertebral fracture and
non-vertebral fractures odd ratios for TERIPARATIDE vs. PTH 1-84 from the MTC of
Migliore (2012).The odd ratios are held constant for the 18 months of treatment.
The analysis was carried out from the perspective of the Italian health care system
and therefore only direct costs were considered (drug costs and fracture costs).
Vertebral and non-vertebral fracture costs for Italy were taken from Borgstrom
(2011) and inflated to year 2012 using a national inflation index. The average non-
vertebral fracture cost was calculated by adjusting the non-vertebral fracture costs
to the probability of their incidence. The model integrates a univariate sensitivity
analysis and a probabilistic sensitivity analysis. RESULTS: Within 500 Monte Carlo
patient simulations, mean costs per patient were significantly different between
the two alternatives with €11,408 (SD €4,478) and €13,280 (SD €4,643) for the TERIPA-
RATIDE and PTH 1-84 group, respectively (p  0.0001). The robustness of the study
was confirmed through the univariate sensitivity analysis that has shown TERIPA-
RATIDE to remain the cheapest therapeutic option also by decreasing the vertebral
fractures odd ratio of PTH 1-84 up to 50% and through the probabilistic sensitivity
analysis where TERIPARATIDE has shown the highest probability to be the cheap-
est therapeutic option. CONCLUSIONS: Considering the treatment costs and the
costs of the fractures not avoided, TERIPARATIDE is expected to be the cheapest
therapeutic option compared to PTH 1-84.
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OBJECTIVES: Examine the impact of a claims-based severity index for rheumatoid
arthritis (RA) on health care costs and utilizations of RA patients using large U.S.
claims data. METHODS: Adult patients with at least two RA diagnoses and 12
months of continuous health plan enrollment before and after the index date (first
RA diagnosis date) were identified from a large U.S. claims database (10/1/2008 -
09/30/2009). A severity index for rheumatoid arthritis (SIFRA) was developed by
calculating a weighted sum of 34 RA-related indicators including laboratory, clin-
ical and functional status, extra-articular manifestations, surgical history, and
medications as assessed by an expert Delphi panel of six rheumatologists. The
relationship between SIFRA terciles and health care utilizations and costs was also
examined using histograms. A regression model was used to examine the improve-
ment of the model fitting by adding SIFRA. RESULTS: A total of 23,951 RA patients
(mean SIFRA: 9.14) with laboratory information were identified. Descriptive analy-
sis showed that patients in the upper tercile of SIFRA incurred $9,123 more all-
cause health care costs and $1,326 more RA-related health care costs than patients
in the lower tercile of SIFRA. The most dramatic difference between highest and
lowest SIFRA terciles occurred with pharmacy costs ($6,860 vs. $1,919, p0.001).
Health care visits followed a similar to health care costs for SIFRA terciles. Patients
in the highest SIFRA tercile had higher total office visits (110.14 vs. 77.16, p0.001)
and higher RA-related visits (6.72 vs. 3.93, p0.001) compared to patients in the
lowest tercile. Regression results showed that the model was more than 6-times
(611%) superior in explaining the variation in outcomes after adding SIFRA into the
model. CONCLUSIONS: SIFRA demonstrated evidence of being a significant deter-
minant of health care costs and utilizations for RA patients. This study suggests
that SIFRA could be an important methodological tool to control for severity in
RA-related outcomes research.
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OBJECTIVES: Estimate risk-adjusted health care costs and identify associated risk
factors for ankylosing spondylitis (AS) expenditures in Turkey using real-world
data. METHODS: Research-identified data from a system that processes claims for
all Turkish health insurance funds was analyzed. Adult prevalent AS patients with
two AS visits at least 60 days apart, identified between June 1, 2010 and December
31, 2010, were required to have an AS diagnosis before June 1, 2010, with at least 1
year of continuous enrollment for the baseline and follow-up years. Pharmacy,
outpatient and inpatient claims were compiled over the study period for the se-
lected patients. RESULTS: Among 2,383 patients (mean age: 40.52; female: 38%),
51% were age 18-39, 46% were 40-64 years and 3% were age 65 or older. AS diagnoses
were most prevalent in the Marmara region (46%), followed by Aegean (17%), Cen-
tral Anatolia (22%), and Mediterranean (8%). Nearly 40% of AS patients had at least
one cardiovascular, diabetic, respiratory, allergy, Crohn’s disease, uveit and rheu-
matoid arthritis comorbid condition prior to AS diagnosis. 7% of patients were
hospitalized and 46% had at least one outpatient visit during the pre-index period.
Most patients were prescribed non-COX inhibitors (71%) and 35% of patients were
prescribed disease-modifying anti-rheumatic drugs (DMARDs). Few patients (1%)
had surgery prior to diagnosis. The total annual cost (a4,233) was comprised of
mainly pharmacy (a3,760), followed by outpatient (a297), and inpatient costs (a155),
and an average copay of a21. Prior comorbid conditions including diabetes, respi-
ratory disease as well as hospitalization, glucocorticoid and DMARD use signifi-
cantly contributed to annual health care costs, unlike gender and age.
CONCLUSIONS: Annual costs of AS patients are significantly lower in Turkey rela-
tive to other European countries, yet, pharmaceutical expenditures cover a signif-
icant portion of the overall cost. Comparative effectiveness studies are needed to
further decrease pharmaceutical expenditures for AS treatment.
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